Articles

Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia

Department of Hematology and Lymphoma and Myeloma Center Amsterdam, Academic Medical Center, Amsterdam
Department of Hematology and Lymphoma and Myeloma Center Amsterdam, Academic Medical Center, Amsterdam
Department of Hematology - HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam
Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht
Department of Hematology and Lymphoma and Myeloma Center Amsterdam, Academic Medical Center, Amsterdam
Department of Internal Medicine, Reinier de Graaf Hospital, Delft;Department of Hematology, Leiden University Medical Center
Department of Hematology, Haga Hospital, the Hague
Department of Hematology, VU University Medical Center, Amsterdam
Department of Hematology, University Medical Center, Groningen
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam
Department of Hematology, Maastricht University Medical Center
Department of Internal Medicine, Medical Center, Leeuwarden
Department of Internal Medicine, Ikazia Hospital, Rotterdam
Department of Internal Medicine, Gelderland Valley Hospital, Ede
Department of Medical Oncology, Antoni van Leeuwenhoek Hospital, Amsterdam
Department of Hematology, Leiden University Medical Center
Department of Hematology, University Medical Center, Utrecht
Department of Hematology, Medical Spectrum Twente, Enschede
Laboratory Special Hematology, Academic Medical Center, Amsterdam, the Netherlands
Department of Hematology, Haga Hospital, the Hague
Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht
Vol. 104 No. 1 (2019): January, 2019 https://doi.org/10.3324/haematol.2018.193854